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Background
Studies have provided conflicting data for calendar
trends in anal cancer among HIV+ individuals, one of
the most frequent cancers in this population. Our objec-
tive here was to compare the risk of anal cancer
between HIV+ and HIV- individuals in North America,
and how this relationship has changed over time.
Methods
We conducted a cohort study involving 12 cohorts from
North America followed between 1996 and 2007. Anal
cancer incidence rates were compared between HIV+
men who have sex with men (MSM), HIV+ non-MSM
(including women), and HIV- individuals. We calculated
rate ratios (RRs) using multivariable Poisson regression
with adjustment for age, sex, race/ethnicity (26%
imputed), and calendar era. We next determined
whether the adjusted RR for HIV+ compared with HIV-
controls has changed over time. Since only a subset of
cohorts contributed HIV- controls, we also computed
age- and sex- and race-standardized incidence ratios
(SIR) using national U.S. SEER rates.
Results
Cohort-specific HIV+ anal cancer incidence rates ranged
across cohorts from 0 to 154 cases per 100,000 person-
years. The cohort-specific prevalence of MSM explained
58% of the total variability in rates. Overall, there were
111 anal cancer diagnoses among 15,907 HIV+ MSM,
38 diagnoses among 18,239 HIV+ non-MSM, and 79
diagnoses among 115,469 HIV- individuals. The corre-
sponding adjusted RRs were 66.6 (95% CI: 36.9-120.2)
for HIV+ MSM and 23.4 (95% CI: 11.9-46.1) for HIV+
non-MSM compared with the HIV- control group. For
both HIV+ MSM and non-MSM, the RR was highest in
1999-2002, but the RR decreased for both groups in the
most recent calendar era, 2003-2007 (Table 1), although
the differences were not statistically significant (p>0.2)
comparing RRs across eras. Inferences were similar for
SIRs.
Conclusions
Despite an aging HIV+ population with presumed
longer exposure to the oncogenic effects of human
papillomavirus, the relative incidence of anal cancer
among HIV+ individuals in the most recent calendar era
has not increased. It is possible that improvements in
immune function resulting from effective antiretroviral
therapy contributed to this result.
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Table 1 Anal cancer RR (95% CI) for HIV+ MSM and HIV+
non-MSM compared with HIV- controls (reference) and
national US SEER rates
RR (MSM)
RR (non-
MSM) SIR (MSM)
SIR (non-
MSM)
1996 to
1998
97.7 (12.3-
774.3)
12.0 (0.7-
195.5)
63.5 (29.0-
120.6)
10.2 (0.3-
56.9)
1999 to
2002
114.7 (35.3-
372.8)
35.2 (9.8-
126.5)
117.3 (84.5-
158.5)
26.4 (11.4-
52.0)
2003 to
2007
48.1 (23.6-
98.2)
19.7 (8.8-
44.1)
77.7 (59.3-
100.0)
26.4 (14.8-
43.5)
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